Who takes the blame when a drug grows, yet disappoints Wall Street? That’s the challenge of pharma commercial accountability: figuring out whether the brand, the market, or the forecast fell short. Alnylam Pharmaceuticals’ search for a new chief commercialization officer has put Amvuttra (vutrisiran) under another spotlight. Yet revenue, physician adoption, payer coverage, and investor expectations rarely move at the same speed. Before declaring a brand or commercial team a failure, leaders need to ask what the evidence actually shows.
Table of Contents
- Alnylam and the Expectations Gap
- Brand Positioning, Market Access, and Field Execution
- When the Forecast Is Wrong, Growth Can Look Like Failure
- Building a Fairer Model for Commercial Leadership
- Conclusion
- Frequently Asked Questions
Alnylam’s Amvuttra Story Is Bigger Than a Sales Number
On November 4, 2026, Alnylam announced that Tolga Tanguler would leave his role as chief commercialization officer and that a search firm would help select a successor. The company described the transition as it prepared for its next phase of growth. Importantly, it did not say weak sales triggered his departure. While the move invites questions about commercial leadership, it should not be treated as proof that performance caused the change.
Indeed, the sales picture is more complex than a simple miss. Alnylam reported $1.13 billion in third-quarter 2026 Amvuttra net product revenue, up 65% from a year earlier. However, in July, the company lowered its full-year revenue guidance for its TTR franchise, which includes Amvuttra and Onpattro, from $4.4 billion to $4.7 billion down to $4.2 billion to $4.5 billion. It maintained that revised range in October. The company had explained that its revised outlook partly reflected slower growth in second-line treatment after an initial wave of patient demand.
That gap between strong sales growth and investor expectations raises a difficult question: was the problem commercial performance, or were the original forecasts too optimistic? A rising sales line can still disappoint when the original plan assumed faster adoption. Consequently, a careful review must distinguish weaker execution from assumptions that no longer match the market.
Look Beyond Brand Positioning to Market Access and Execution
Before judging a pharmaceutical launch, ask whether physicians understand the treatment’s value, patients can reach care, and field teams engage appropriate prescribers. Also ask whether competitors or prescribing habits have changed. Positioning problems arise when clinicians know a medicine but remain unclear about its place in care. By contrast, execution problems appear when a sound strategy fails to reach the right clinicians or respond to local needs.
Access barriers leave a different trail. Physician interest may be high, but coverage rules, approval delays, or patient costs can hold up treatment. Similarly, slow diagnosis can limit demand before anyone writes a prescription. For conditions such as transthyretin amyloid cardiomyopathy (ATTR-CM), identifying eligible patients and connecting them with specialist care are important steps in the treatment journey.
Consequently, even an effective advertising campaign cannot solve every commercial challenge. Digital engagement can improve awareness and support physician education, but it cannot eliminate reimbursement restrictions. Companies working with pharmaceutical digital marketing specialists should connect campaign goals with realistic access and treatment expectations.
As Pharma Marketing Network’s analysis of integrated commercialization suggests, brand strategy, scientific evidence, and market access increasingly need to work together. A brand’s results should therefore be evaluated across the entire patient journey, rather than through sales activity alone.
When the Forecast Is Wrong, Growth Can Look Like Failure
Forecasts can turn a growing product into a perceived disappointment. For example, a plan may assume patients are identified quickly, specialist capacity expands, and prescriptions translate promptly into treatment. Yet those assumptions can prove optimistic without any single team making a clear mistake.
To test the model, commercial teams should compare projected and actual patient progress through diagnosis, treatment eligibility, prescription, approval, treatment start, and ongoing care. Next, examine differences by payer, geography, and prescriber type. Are prescriptions growing while treatment starts lag? If so, investigate approval and onboarding delays. Are treatment starts healthy but ongoing treatment rates below expectations? Then review treatment persistence and patient follow-up before increasing marketing spending.
Revenue also includes timing effects. In its third-quarter 2026 financial update, Alnylam reported that sequential U.S. TTR revenue growth included increased patient demand, a $17 million inventory benefit, and approximately $10 million in favorable gross-to-net adjustments. These details matter because reported revenue does not always reflect changes in underlying patient demand.
Therefore, leaders must separate actual treatment growth from shipment timing and net pricing before rewriting forecasts. In pharma, commercial accountability starts with understanding why actual sales differ from forecasts, rather than simply blaming the executive responsible for hitting the target.
Build a Shared Scorecard Before Assigning Blame
A useful commercial performance review starts with evidence, not a verdict. Commercial leaders should answer for positioning and field decisions. Meanwhile, market access teams should explain reimbursement obstacles, analytics teams should test forecast quality, and senior executives should revisit assumptions and budgets they approved. Shared accountability does not mean nobody is responsible. Instead, it makes responsibility more precise.
A practical scorecard tracks diagnosis trends, prescriber reach, patient starts, reimbursement delays, treatment persistence, competitor activity, and forecast accuracy. Then, assign an owner and a testable explanation to every significant performance gap. Crucially, separate actions the company can change from market forces it cannot control. A competitor’s launch or slower-than-expected diagnosis rate may require a new plan rather than a new leader.
This approach also keeps strategy flexible. As our guide to post-launch pharma marketing explains, pharmaceutical brands need to adapt after launch instead of relying on early momentum. Market conditions change, treatment patterns evolve, and competitive pressures can shift quickly.
Ultimately, holding commercial teams accountable should lead to better decisions, stronger strategies, and more realistic expectations, not simply finding someone to blame. The most valuable performance reviews reveal what needs to change and who is best positioned to make those changes happen.
Conclusion
Alnylam’s leadership change invites questions, but it does not answer them. Amvuttra’s growth, revised outlook, and investor concerns show how quickly an expectations gap can become a commercial narrative. Therefore, pharmaceutical leaders should investigate positioning, market access, field execution, competitive dynamics, and forecasting assumptions before deciding what failed.
Strong commercial leadership requires more than meeting a sales target. It also means recognizing when market conditions have changed, questioning unrealistic projections, and making informed adjustments. Better analysis supports fairer decisions and smarter long-term growth.
Frequently Asked Questions
What is pharma commercial accountability?
It is the practice of measuring pharmaceutical commercial results, understanding why performance differs from expectations, and assigning responsibility for decisions teams can influence. It includes brand strategy, sales execution, market access, and forecasting.
Does a missed sales forecast mean a drug launch has failed?
Not necessarily. A drug may experience strong sales growth while still falling short of an optimistic forecast. Leaders should examine patient demand, treatment access, competitive activity, and forecasting assumptions before judging the launch.
How can pharmaceutical companies distinguish market access problems from sales execution problems?
Companies can compare physician interest, prescription activity, reimbursement approvals, and treatment starts. Strong prescribing demand combined with delayed patient starts may indicate access barriers rather than weak field execution.
Why are pharmaceutical sales forecasts sometimes inaccurate?
Forecasts depend on assumptions about diagnosis rates, physician adoption, payer coverage, competition, and treatment demand. When these factors change or develop more slowly than expected, actual revenue may differ from projections.
Did Alnylam blame Amvuttra sales for its commercial leadership change?
No. Alnylam’s November 4, 2026 announcement confirmed the leadership transition but did not identify Amvuttra’s commercial performance as the reason. The company’s reported sales growth and revised revenue outlook should be examined separately from assumptions about the executive change.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
